NOTABLE LABS LTD (NTBL)
IL0012002452 - Common Stock
Taking everything into account, NTBL scores 1 out of 10 in our fundamental rating. NTBL was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of NTBL have multiple concerns. NTBL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
NTBL had negative earnings in the past year.
In the past year NTBL has reported a negative cash flow from operations.
In the past 5 years NTBL always reported negative net income.
In the past 5 years NTBL always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -152.09%, NTBL is not doing good in the industry: 86.15% of the companies in the same industry are doing better.
NTBL has a worse Return On Equity (-232.90%) than 71.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| ROIC | N/A |
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NTBL's Gross Margin of 37.70% is fine compared to the rest of the industry. NTBL outperforms 76.91% of its industry peers.
In the last couple of years the Gross Margin of NTBL has declined.
NTBL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
2. Health
2.1 Basic Checks
NTBL does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTBL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NTBL has more shares outstanding
The debt/assets ratio for NTBL is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -16.80, we must say that NTBL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -16.80, NTBL is not doing good in the industry: 84.55% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.03 indicates that NTBL is not too dependend on debt financing.
NTBL has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: NTBL outperforms 41.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.8 |
ROIC/WACCN/A
WACC10.75%
2.3 Liquidity
A Current Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
NTBL has a worse Current ratio (2.77) than 68.56% of its industry peers.
A Quick Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
NTBL has a Quick ratio of 2.77. This is in the lower half of the industry: NTBL underperforms 67.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.77 | ||
| Quick Ratio | 2.77 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 65.56% over the past year.
Looking at the last year, NTBL shows a very negative growth in Revenue. The Revenue has decreased by -34.79% in the last year.
The Revenue for NTBL have been decreasing by -12.08% on average. This is quite bad
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NTBL will show a very negative growth in Earnings Per Share. The EPS will decrease by -63.21% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTBL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTBL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NTBL's earnings are expected to decrease with -63.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.21%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NTBL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOTABLE LABS LTD
NASDAQ:NTBL (10/22/2024, 8:00:02 PM)
After market: 0.2456 0 (-0.93%)0.2479
-0.09 (-27.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.39M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.09% | ||
| ROE | -232.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.7% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.77 | ||
| Quick Ratio | 2.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-81.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y